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Abstract
Objective—Heme oxygenase-1 induction (HO-1) elicits chronic weight loss in several rodent
models of obesity. Despite these findings, the mechanism by which HO-1 induction reduces body
weight is unclear. Chronic HO-1 induction does not alter food intake suggesting other mechanisms
such as increases in metabolism and activity may be responsible for the observed reduction of
body weight. In this study, we investigated the mechanism of weight loss elicited by chronic HO-1
induction in a model of genetic obesity due to melanocortin-4 receptor (MC4R) deficiency.
Design—Experiments were performed on loxTB MC4R deficient mice as well as lean controls.
Mice were administered cobalt protoporphyrin (CoPP, 5 mg/kg), an inducer of HO-1, once weekly
from 4 to 23 weeks of age. Body weights were measured weekly and fasted blood glucose and
insulin as well as food intake were determined at 18 weeks of age. O2 consumption, CO2
production, activity, and body heat production were measured at 20 weeks of age.
Results—Chronic CoPP treatment resulted in a significant decrease in body weight from 5
weeks on in loxTB mice. Chronic CoPP treatment resulted in a significant decrease in fasted blood
glucose levels, plasma insulin, and a significant increase in plasma adiponectin levels in MC4R
deficient mice. Chronic CoPP treatment increased O2 consumption (47 ± 4 vs. 38 ± 3 ml/kg/min,
P<0.05) and CO2 production (44 ± 7 vs. 34 ± 4 ml/kg/min, P<0.05) in treated versus non-treated,
MC4R deficient mice (n=4). Heat production (10%) and activity (18%) were also significantly
(P<0.05) increased in CoPP treated MC4R deficient mice.
Conclusion—Our results suggest that chronic HO-1 induction with CoPP induction elicits
weight loss by increasing metabolism and activity by an MC4R independent pathway.
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Cobalt protoporphyrin (CoPP), an inducer of heme oxygenase (HO)-1, has been reported to
elicit chronic weight loss in a variety of species including dogs, chickens, rats, and mice (1).
This effect of HO induction on body weight has been replicated with other systemic
inducers of HO-1 such as D-4F which is an apolipoprotein A1 mimetic peptide (2;3). While
the affects of chronic HO induction on body weight have been established, the mechanism
leading to weight loss has not been determined. Previous studies have demonstrated that
direct injection of CoPP into either the lateral ventricles or directly into the medial nuclei of
the hypothalamus results in acute decreases in food intake but chronic decreases in body
weight (4;5). Central CoPP administration has also been associated with decreases in the
acute feeding response to neuropeptide Y (NPY) as well as in neuronal nitric oxide synthase
(nNOS) activity but increases nNOS message and protein (6-8). Despite exerting only acute
effects on appetite, the effects of CoPP on body weight are persistent suggesting a
mechanism independent of caloric intake mediates the chronic weight loss elicited by CoPP
treatment.
Leptin, a hormone released from adipocytes, regulates appetite by stimulating the release of
α-melanocyte-stimulating hormone (α-MSH) from pro-opiomelanocortin (POMC) neurons
of the hypothalamus which in turn binds to melanocortin-3 and 4 receptors (MC3/4R) to
mediate the metabolic and cardiovascular effects of leptin (9). Two mouse models of MC4R
deficiency have been developed to examine the mechanism by which loss of MC4R
receptors leads to obesity. The first model is a traditional gene-targeted deletion of the
endogenous MC4R receptor (10). In these mice, most of the MC4R receptor coding region
which is contained in a single exon has been eliminated. In the second model of MC4R
deficiency, a transcriptional blocker flanked by loxP sites was placed between the
transcription start site and the initiation ATG of the MC4R gene which causes disruption of
the transcription of the gene resulting in MC4R deficiency (loxTB mice) (11). In loxTB
mice, function of the endogenous MC4R can be “rescued” by selective expression of the Cre
recombinase which deletes the transcription blocker and restores endogenous expression of
the MC4R gene. Both models develop obesity, hyperphagia, hyperglycemia, and
hyperinsulinemia resulting from disruption of the MC4R gene (10;11). Loss of the MC4R is
associated with decreases in oxygen consumption (VO2) suggesting that a metabolic defect
may also responsible for the development of obesity in both of these models (11;12).
Mutations in MC4Rs are the most prevalent cause of genetic obesity in humans (13-15).
These findings underscore the important role for MC4R activation in the regulation of body
weight and metabolism. Obese loxTB MC4R deficient mice were utilized to specifically
examine the importance of the central MC4R system in mediating weight loss elicited by
chronic HO-1 induction. We also directly measured VO2, carbon dioxide production
(VCO2), locomotor activity and heat production to determine the role of metabolism in the
chronic weight loss elicited by HO-1 induction. Mice were treated weekly with CoPP for 19
weeks and then housed in specific metabolic cages for the measurement of oxygen




Experiments were performed on male C57BL/6J (Jackson Labs, Bar Harbor, ME, USA),
loxTB MC4R deficient mice which were obtained from initial stocks kindly provided by Dr.
Bradford B. Lowell, Harvard Medical School and MC4R gene knockout (KO) mice which
were obtained from initial stocks kindly provided by Dr. Roger D. Cone, Vanderbilt
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University (10;11). LoxTB MC4R deficient mice were bred at the University of Mississippi
Medical Center and maintained on a mixed C57BL/6 and 129Sv background. MC4R KO
mice were also bred at the University of Mississippi Medical Center and maintained on a
C57BL/6 genetic background. Mice were treated with once weekly injections of CoPP (5
mg/kg, s.c., Frontier Scientific, Logan, UT, USA) from 4 weeks to 23 weeks of age. The
mice were fed a standard laboratory diet and were provided water ad libitum. All animal
protocols were approved by the Institutional Animal Care and Use Committee at the
University of Mississippi Medical Center and performed in accordance with the Guide for
the Care and Use of Laboratory Animals of the U.S. National Institutes of Health. Mice
were housed together during the experimental study and were weighed weekly for
measurement of body weight. Food intake was determined in individually housed mice at 18
weeks of age by daily weighing of food provided to the mice over a 5 day period. O2
consumption, CO2 production, activity, and body heat production were measured at 20
weeks of age in mice placed in specially designed cages as described below. Mice were
housed in rooms with an ambient temperature of 74°F with 12 hours of light (6AM-6PM)
and 13 hours of dark (6PM-6AM). Mice were euthanized at 30 weeks at which time organs
were collected and weighed.
Plasma Measurements
Blood was obtained from mice at 19 weeks of age by retro-orbital bleed under light
isoflurane anesthesia. All mice were fasted overnight prior to blood sample collections.
Whole blood samples were collected into EDTA containing tubes and centrifuged at 3,000 g
for 5 min at 4°C. Plasma was then collected and stored at -20°C until use. Blood glucose
concentration was immediately determined from a 5 ul blood sample with the Accuchek
Advantage glucometer (Roche, Madison, WI, USA). Plasma insulin levels were measured
by ELISA with the Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem, Inc., Downers
Grove, IL, USA). Plasma adiponectin levels were also measured by ELISA with the Mouse
Adiponectin ELSIA Kit (Millipore, Billerica, MA, USA).
Oxygen consumption, carbon dioxide & heat production, respiratory quotient motor
activity
At 20 weeks of age, mice were placed individually in metabolic cages (AccuScan
Instruments Inc, Columbus, OH) equipped with oxygen sensors to measure oxygen
consumption (VO2), carbon dioxide sensors to measure carbon dioxide production (VCO2),
and infrared beams to determine motor activity. VO2 was measured for 2-min at 10-minute
intervals continuously 24-hours a day using a Zirconia oxygen sensor. Respiratory quotient
(RQ) was automatically calculated by the software and expressed as VCO2/VO2. Motor
activity was determined using infrared light beams mounted in the cages in X, Y and Z axes.
Heat production was derived from the measurement of VO2 and VCO2 which were used to
compute the calorific value and then applied to the volume of gases exchanged to compute
heat production. After the mice were acclimatized to the new environment for 3 days, VO2,
VCO2, activity and heat production were recorded for 3 consecutive days. The values for
each of these parameters were then averaged for each individual mouse.
Western Blots
Western Blots were performed on lysates prepared from adipose tissue, liver, and muscle.
Samples of 30 μg of protein were boiled in Laemmli sample buffer (Bio-Rad, Hercules, CA)
for 5 min, electrophoresed on 12 or 10% SDS-polyacrylamide gels, and blotted onto
nitrocellulose membrane. Membranes were blocked with Odyssey blocking buffer (LI-COR,
Lincoln, NE) for 2 hours at room temperature, then incubated with the following antibodies:
mouse anti-HO-1 antibody (StressGen, Vancouver, Canada, 1:2000), rabbit anti-pAMPK
(Cell Signaling Technology, Danvers, MA, 1:1000), rabbit anti-pAKT (Cell Signaling
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Technology, Danvers, MA, 1:1000), mouse anti-glucose transporter 4 (Glut-4) (Abcam
Cambridge, MA, 1:2,500), mouse anti-GAPDH monoclonal antibody (Abcam, 1:20,000),
rabbit or mouse anti-β-actin antibody (Abcam, 1:5,000) overnight at 4°C. The membranes
were then incubated with Alexa 680 goat anti-mouse IgG (Invitrogen, Carlsbad, CA
1:5,000) and IRDye 800 goat anti-rabbit IgG (Rockland, Gilbertsville, PA, 1:5,000) or Alexa
680 donkey anti-rabbit IgG (Invitrogen, 1:5,000) or IRDye 800 donkey anti-mouse IgG
(Rockland, 1:5,000) for 1 hour at room temperature. The membranes were then visualized
using an Odyssey infrared imager (Li-COR, Lincoln, NE). Densitometric analysis was
performed using Odyssey software (LI-COR). Protein levels are expressed as a ratio to the
level of β-actin in adipose and liver and to the level of GAPDH in muscle to normalize for
protein loading.
Statistical analyses
All data are presented as mean ± s.e.m. Differences between treatment groups were
determined using unpaired T-Tests or one-way analysis of variance with a post hoc test
(Dunnett’s). A P<0.05 was considered to be significant. All analyses were performed with
SigmaStat (Systat software, Inc., Richmond, CA, USA).
Results
Effect of chronic CoPP treatment on body weight, food intake, and fat distribution
Chronic treatment with CoPP (5 mg/kg/wk) significantly attenuated body weight gain in
loxTB mice while having no effect on body weight- gain in control C57BL/6J mice (Figure
1). The effect of chronic CoPP treatment on body weight was also confirmed in MC4R KO
mice (Figure 1). CoPP treated MC4R KO mice exhibited body weights similar to control
mice. LoxTB mice exhibited greater obesity from 5 weeks of treatment as compared to
MC4R KO mice. CoPP treatment in loxTB significantly attenuated weight gain which
resembled the pattern of weight gain displayed in MC4R KO mice (Figure 1). Food intake,
at 18 weeks of age, was significantly increased in both models of MC4R deficiency as
compared to control mice averaging 3.5 ± 0.2, vs. 5.0 ± 0.2, vs. 4.7 ± 0.3 grams/day in
control, MC4R KO, and loxTB mice, respectively (P<0.05 vs. control). CoPP treatment had
no effect on food intake in any of the groups studied with food intake averaging 3.7 ± 0.1,
vs. 5.0 ± 0.3, vs. 4.7 ± 0.2 grams/day in control, MC4R KO, and loxTB mice, respectively.
Chronic CoPP treatment had a significant effect on fat distribution in all groups studied.
CoPP treatment significantly decreased epidydimal fat in control and MC4R KO mice but
had no effect in loxTB mice while significantly decreasing visceral fat in MC4R KO and
loxTB mice but not in control mice (Figure 2). CoPP treatment resulted in a significant
decrease in total fat in all groups (Figure 2).
Effect of chronic CoPP treatment on blood glucose, insulin and adiponectin levels
Fasting blood glucose levels were significantly increased in both loxTB and MC4R KO
mice as compared to control mice. Chronic CoPP treatment equivalently lowered fasting
blood glucose levels in both loxTB and MC4R KO mice but had no effect on fasting blood
glucose levels in control mice (Figure 3A). Both models of MC4R deficiency exhibited
increased fasting insulin levels as compared with control mice (Figure 3B). However,
plasma insulin levels were significantly higher in loxTB mice as compared to MC4R KO
mice. CoPP treatment significantly decreased fasting insulin levels in both models of MC4R
deficiency. Plasma adiponectin levels in loxTB mice were significantly decreased as
compared to control mice under basal conditions (Figure 3C). This finding was also
confirmed in MC4R KO mice (Figure 3C). CoPP treatment significantly increased plasma
adiponectin levels in all groups; however, the increase in the MC4R deficient mice was
close to 4 fold as compared to a 70% increase exhibited in control mice (Figure 3C).
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Effect of chronic CoPP treatment on oxygen (O2) consumption and carbon dioxide (CO2)
production, and respiratory quotient (RQ)
Basal O2 consumption was significantly decreased in MC4R deficient loxTB mice as
compared to control mice when normalized for total body mass (Figure 4A, left panel).
However, Basal O2 consumption when not normalized to body weight was not different in
MC4R deficient loxTB mice as compared to control mice (Figure 4A, right panel). Chronic
CoPP treatment significantly increased O2 consumption by 20% in control mice and 28% in
loxTB mice irrespective normalization (Figure 4A). Basal CO2 production was significantly
decreases in loxTB mice as compared to control mice when normalized for total body mass
(Figure 4B, left panel). Basal CO2 production when not normalized to body weight was
significantly increased in loxTB mice as compared to control mice (Figure 4B, right panel).
Chronic CoPP treatment significantly increased CO2 production by 17% in control mice and
28% in loxTB mice and this effect was even more dramatic in loxTB mice when not
normalized to body mass (Figure 4B). Chronic CoPP treatment had no effect on 24 hour RQ
in loxTB which averaged 0.9 + .02 vs. 0.88 + .04 VO2/VCO2 in loxTB vs. CoPP treated
loxTB mice. There was a trend for a decrease in RQ during the day time in CoPP treated
loxTB mice with RQ averaging .87 + .01 vs. .82 + .02 VO2/VCO2 in each group
respectively. CoPP treatment had no effect on 24 hour RQ in control mice with RQ values
averaging 0.83 + .01 VO2/VCO2 in both each group.
Effect of chronic CoPP treatment on heat production and activity
Chronic CoPP treatment had a similar effect to increase heat production in both control and
loxTB treated mice (Figure 5A). CoPP treatment had no significant effect on locomotor
activity in control mice; however, it did significantly increase locomotor activity in MC4R
deficient loxTB mice (Figure 5B).
Effect of chronic CoPP treatment on metabolic pathways in adipose tissue, liver and
muscle
Chronic CoPP treatment induced HO-1 protein in the adipose tissue of loxTB mice (Figure
6A & B). The induction of HO-1 in the adipose tissue was also associated with increases in
pAKT (Figure 6A &C), pAMPK (Figure 6A & D), pMTOR (Figure 6A & E), and Glut 4
(Figure 6A &F). Chronic CoPP treatment induced HO-1 protein in the liver of loxTB mice
(Figure 7A &B). However, induction of HO-1 in the liver was not associated with changes
in the levels of pAKT (Figure 7A &C), pAMPK (Figure 7A & D), or Glut 4 (Figure 7A &
F). Hepatic induction of HO-1 was associated with a decrease in the levels of pMTOR
(Figure 7A &E) in loxTB treated mice. Chronic CoPP treatment resulted in significant HO-1
induction in gastrocnemius muscle of loxTB mice (Figures 8A & B). Induction of HO-1 in
the muscle was associated with no changes in the levels of pAMPK (Figures 8A & C) but
resulted in a significant decrease in the levels of Glut 4 (Figures 8A & D).
Discussion
We directly examined the effects of chronic HO-1 induction with CoPP on O2 consumption,
CO2 and heat production, and locomotor activity in a mouse model of obesity resulting from
MC4R deficiency. Chronic CoPP treatment increased in both O2 consumption and CO2
production and lowered body weight in obese loxTB MC4R deficient mice. An underlying
decrease in metabolism in MC4R deficient mice is believed to be the initial driving force
behind the obesity as hyperphagia in this model is not observed until after 14 weeks of age
(12). Our results in the present study are consistent with these findings as we observed a
significant increase in food intake in the obese MC4R deficient mice at 18 weeks of age as
compared to control lean mice. Also consistent with previous studies (4;5), we did not
observe any effect of chronic CoPP treatment on food intake at this later time point of
Csongradi et al. Page 5













administration. However, since food intake was not measured throughout the entire study,
the potential importance of any initial decrease in food intake to the chronic weight
reduction in CoPP treated MC4R deficient mice cannot be excluded. It is possible that early
decreases in food intake in the MC4R deficient mice promote weight loss and this is
maintained through increases in activity which maintain the initial weight loss. While this is
possible scenario for the action of CoPP in MC4R deficient mice, several observations
would argue against this as the mechanism for sustained weight loss in this model. First,
decreases in food intake are generally associated with decreases in metabolism which were
not observed in CoPP treated MC4R deficient or control lean mice. Next, while CoPP acted
to increase O2 consumption, heat production, and adiponectin levels in both lean and obese
mice, only obese MC4R deficient exhibited increases in activity which were most likely the
result of decreased body weight driven by increased O2 consumption since food intake was
not chronically decreased in the MC4R deficient mice.
Chronic CoPP treatment increased in both O2 consumption and CO2 production in obese
loxTB MC4R deficient mice which had significantly lower O2 consumption and CO2
production under basal conditions as compared to lean control mice when corrected for total
body mass. This finding is in agreement with previous studies in MC4R deficient mice
which also found decreased oxygen consumption (11;12). It is noteworthy that in these
studies O2 consumption is normalized to total body mass as well. The underlying decrease in
metabolism in MC4R deficient mice is believed to be the initial driving force behind the
obesity as hyperphagia in this model is not observed until after 14 weeks of age (12). Our
results in the present study are consistent with these findings as we observed a significant
increase in food intake in the obese MC4R deficient mice at 18 weeks of age as compared to
control lean mice. However, in the present study, we did not detect any differences in basal
O2 consumption between obese MC4R deficient and lean mice and observed a greater
VCO2 in MC4R deficient as compared to lean mice when no correction for body mass was
made. Normalization of metabolic data is an area of great controversy that was recently
addressed in an excellent review (16). The body composition between MC4R deficient mice
and lean control mice differs in the amount of lean versus fat mass in each model. In order to
account for the differences in lean versus fat mass between the models the amounts of each
tissue mass would need to be measured using non-invasive methods such as duel-energy X-
ray absorptiometry or nuclear magnetic resonance imaging. These measurements were not
performed in the current study. Despite the discrepancy between the values for VO2 and
VCO2 between the MC4R deficient and lean mice depending on the normalization method
used, the effects of chronic CoPP treatment to increase both of these parameters were
consistent irrespective of how the data was normalized.
Chronic CoPP treatment resulted in a significant increase in O2 consumption, heat
production and locomotor activity in obese loxTB MC4R deficient mice. While the exact
mechanism by which chronic induction of HO-1 affects these metabolic parameters is
unknown, one potential target of HO-1 induction is the mitochondria. Previous studies have
demonstrated that HO-1 localizes to the mitochondria where it can affect the levels of
mitochondrial transport proteins (17-19). Further studies of cardiac myocytes have
demonstrated that the HO metabolite, carbon monoxide (CO), is an important regulator of
mitochondrial biogenesis through enhancement of the peroxisome proliferator-activated
receptor gamma-1 (PGC-1) transcriptional co-activator as well as activation of nuclear
respiratory factor 2 (NRF2) (20;21). The increase in mitochondrial biogenesis could result in
an increase in mitochondrial mass in peripheral tissues such as adipose, liver, or muscle
which could in turn increase in O2 consumption. The increase in mitochondrial biogenesis
may also result in greater exercise capacity in the obese loxTB mice and help increase
locomotor activity. This hypothesis is supported by a recent study in humans which
demonstrated increase muscle biogenesis and switching to a more aerobic muscle fiber type
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following intermittent breathing of CO (22). Further studies specifically examining
mitochondrial density and function in obese MC4R deficient mice are needed in order to
fully test this hypothesis.
Chronic CoPP treatment significantly attenuated obesity, lowered blood glucose and insulin,
and increased plasma adiponectin levels in obese, MC4R deficient, loxTB mice. These
findings were confirmed in obese MC4R KO mice as well. The results obtained with chronic
induction of CoPP in MC4R deficient mice are similar to those obtained in another mouse
model of obesity, the leptin deficient ob/ob mouse. HO induction with CoPP in ob/ob mice
had similar effects on weight gain, fat distribution, blood glucose, plasma levels of insulin
and adiponectin all of which were prevented by blockade of HO activity with a specific HO
inhibitor (23). Similar effects on these parameters were also observed after chronic treatment
of ob/ob mice with a different HO inducer, D-4F (2). However, the effects of HO induction
on O2 consumption, CO2 and heat production, and activity in obese ob/ob mice were not
determined in these studies. Our study demonstrates that chronic induction of HO-1 with
CoPP results in increases in O2 consumption, CO2 and heat production, and activity in obese
MC4R deficient mice. Furthermore, it should be noted that treatment with metalloporphyrins
like CoPP may have effects which are mediated independently of HO-1 activation though
such mechanisms as direct activation of soluble guanyl cyclase (24;25). Future experiments
in HO-1 deficient models is one approach to determine if any of the observed effects of
chronic CoPP administration occur independently of HO-1 induction.
Our results support the important role of the recently established HO-1-adiponectin axis in
the lowering of body weight and improvement of insulin sensitivity in obese, MC4R
deficient, loxTB mice. Adiponectin levels were significantly decreased in obese, MC4R
deficient, loxTB mice and were significantly increased by chronic CoPP treatment. Similar
results were also obtained in obese MC4R KO mice. Interestingly, chronic CoPP treatment
resulted in a significant increase in adiponectin levels in lean control mice as well. Several
studies in obese rat and mouse models have revealed an important link between HO-1,
adiponectin and the improvement of insulin-sensitivity and reduction in inflammation in
obesity (2;23;26). Chronic HO-1 induction has been reported to transform the phenotype of
adipocytes in obesity from large, insulin-resistant, cytokine producing to smaller, insulin-
sensitive and adiponectin producing adipocytes (3;27). The mechanism by which induction
of HO-1 increases adiponectin levels is not fully understood but may be related to the ability
of HO-1 to act as a chaperone protein as it is a member of the heat shock protein family
(28). HO-1 may also increase adiponectin levels by its ability to decrease reactive oxygen
species through the production of bilirubin or via stimulation of other important cellular
antioxidants (29;30).
Consistent with the remodeling of adipocytes by chronic HO-1 induction, we observed
significant alterations in important metabolic signaling pathways after chronic CoPP
treatment in loxTB mice. Increases in the levels of phosphorylated AKT, AMPK, mTOR
were observed in the adipocytes of CoPP treated loxTB mice. These results are in agreement
with previous studies in obese leptin deficient, ob/ob mice and in leptin receptor deficient
obese Zucker rats (3;27). Consistent with the improvements in plasma glucose and insulin in
CoPP treated loxTB MC4R deficient mice, we also observed significant increases in glucose
4 transporter (Glut 4) levels in the adipose tissue. While chronic CoPP treatment resulted in
significant enhancement of metabolic pathways in adipose tissue, similar effects were not
observed in the liver or muscle. Chronic HO-1 induction in the liver was not associated with
changes in pAKT, pAMPK or Glut 4 levels and was associated with a decrease in mTOR
levels. Chronic HO-1 induction in the muscle resulted in no changes in the levels of pAMPK
and a decrease in the levels of Glut 4. The decrease in the levels of Glut 4 in the muscle in
response to chronic HO-1 induction is in contrast with previous studies in the rat which
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demonstrated an increase in the levels of Glut 4 after chronic HO-1 induction (31;32). The
reasons for this discrepancy are not known but could be due to species differences in the
metabolic response to chronic HO-1 induction or an effect due to specific loss of MC4R in
the muscle of loxTB mice. Our results suggest that the major effect of chronic HO-1
induction to improve glucose utilization and insulin action occur independently of changes
to the liver or skeletal muscle in obese loxTB MC4R deficient mice.
Central activation of MC3/4R receptors mediates the effects of hormones such as leptin and
serotonin on food intake and energy balance (33-35). Central administration of MC4R
agonists results in increases in metabolic rate and decreases in food intake while similar
administration of MC4R antagonists has the opposite effect on these parameters (36-38).
Chronic HO-1 induction with CoPP resulted in attenuation of weight gain and increases in
metabolism in MC4R deficient loxTB mice. These findings would argue against an essential
role of central MC4R activation in mediating the effects of HO-1 induction on body weight
and metabolism and suggest that changes in these parameters occur via a mechanism
independent of central MC4R activation. However, given the important role for MC3R
receptors in the regulation of metabolism, it is possible that CoPP may act through these
receptors to exert its chronic effects on metabolism (39;40). This possibility needs to be
examined in future studies in MC3R deficient mice. While CoPP administration resulted in
significant attenuation of obesity in both models of MC4R deficiency, the effect was more
pronounced in MC4R KO mice as opposed to loxTB mice. MC4R KO mice exhibited a
greater decrease in epididymal fat that did loxTB deficient mice.
The reason for this differential response in reduction of epididymal fat and total body weight
between the two MC4R deficient models is unknown but may be due to the different genetic
backgrounds of the two strains. MC4R KO mice are on a C57 genetic background while the
loxTB mice are on a mixed 129 genetic background. Further studies will be necessary to
confirm if epigenetic factors in the 129 background contribute to the lack of effect of CoPP
on reduction of epididymal fat and attenuate the anorectic effects of CoPP.
In summary, we report that chronic induction of HO-1 with CoPP significantly increases O2
consumption, heat production and locomotor activity in obese MC4R deficient loxTB mice.
The alterations in these metabolic parameters were associated with a decrease in body
weight and fat distribution which were also confirmed in obese MC4R KO mice. Chronic
CoPP treatment also improved insulin sensitivity, normalized blood glucose levels, and
significantly increased plasma adiponectin levels in obese loxTB and MC4R KO mice.
Chronic CoPP treatment also resulted in increased pAKT, and pAMPK levels in the adipose
tissue of obese loxTB mice. These results demonstrate that chronic CoPP administration
lowers body weight and increases metabolism independent of central MC4R activation and
that increases in metabolism may mediate the anorectic effect of chronic HO-1 induction in
vivo.
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Effect of chronic CoPP treatment on body weight in control C57 mice, melanocortin-4
receptor knockout mice (MC4R-/-), and melanocortin 4 receptor transcriptional blocker
(loxTB) mice. CoPP was administered once weekly. n=6/group.
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Effect of chronic CoPP treatment on distribution of fat in Control, MC4R-/-, and loxTB
mice, n=6/group. Fat pads were weighted from 23 week old mice. *= p<0.05 as compared to
corresponding value in non-treated.
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Plasma measurements in control, MC4R-/-, and loxTB mice. Blood samples were collected
at 19 weeks of age as described in the Methods. A) Blood Glucose, B) Plasma Insulin, C)
Plasma adiponectin. *=P<0.05 as compared to corresponding value in non-CoPP treated
group. †=P<0.05 as compared to corresponding value in control mice. ‡ =P<0.05 as
compared to corresponding value in MC4R-/- mice. n=6/group
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A) Effect of chronic CoPP treatment on 24 hour O2 consumption in control C57 and loxTB
mice normalized to body mass in the left panel and not normalized in the right panel. B)
Effect of chornic CoPP treatment on 24 hour CO2 production in control C57 and loxTB
mice normalized to body mass in the left panel and not normalized in the right panel. * =P<
0.05 as compared to corresponding value in non-CoPP treated mice. † = P<0.05 as
compared to corresponding value in non-CoPP treated control mice, n=4/group.
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Effect of chronic CoPP treatment on A) 24 hour heat production and B) 24 hour locomotor
activity in control C57 and loxTB mice. * =P< 0.05 as compared to corresponding value in
non-CoPP treated mice, n=4/group.
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A) Representative Western blots from adipose tissue of control and CoPP treated loxTB
mice. B) Levels of HO-1 protein. C) Levels of pAKT. D) Levels of pAMPK. E) Levels of
pMTOR. F) Levels of glucose transporter 4 (Glut 4). * =P< 0.05 as compared to
corresponding value in non-CoPP treated mice, n=6/group.
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A) Representative Western blots from liver of control and CoPP treated loxTB mice. B)
Levels of HO-1 protein. C) Levels of pAKT. D) Levels of pAMPK. E) Levels of pMTOR.
F) Levels of glucose transporter 4 (Glut 4). * =P< 0.05 as compared to corresponding value
in non-CoPP treated mice, n=4-6/group.
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A) Representative Western blots from muscle of control and CoPP treated loxTB mice. B)
Levels of HO-1 protein. C) Levels of pAMPK. D) Levels of glucose transporter 4 (Glut 4). *
=P< 0.05 as compared to corresponding value in non-CoPP treated mice, n=6/group.
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